Биомаркеры толерантности и иммунологический мониторинг при трансплантации печени
https://doi.org/10.23873/2074-0506-2020-12-2-126-134
Аннотация
Введение. В обзоре обобщены имеющиеся в литературе сведения о клинических и лабораторных показателях, позволяющих прогнозировать развитие операционной толерантности у реципиентов печени после полной отмены иммуносупрессивной терапии.
Цель обзора – выявить возможные биомаркеры толерантности у реципиентов печени с успешной полной отменой иммуносупрессии для последующего внедрения в повседневную клиническую практику. С позиций прогностической значимости оценены клеточные, гуморальные и молекулярные маркеры операционной толерантности реципиентов печени, которым была полностью отменена иммуносупрессивная терапия без развития дисфункции трансплантата. Обоснована необходимость проведения проспективных исследований для выявления биомаркеров, позволяющих до начала или в процессе снижения иммуносупрессии выявить реципиентов печени, у которых возможна полная ее отмена.
Об авторах
В. Е. Сюткин
ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Россия
Владимир Евгеньевич Сюткин, д-р мед. наук, ведущий научный сотрудник
Н. В. Боровкова
ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Россия
Наталья Валерьевна Боровкова, д-р мед. наук, заведующая научным отделением биотехнологий и трансфузиологии
М. С. Новрузбеков
ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Россия
Мурад Сафтарович Новрузбеков, д-р мед. наук, заведующий научным отделением трансплантации печени
Список литературы
1. Starzl TE. Cell migration and chimerism--a unifying concept in transplantation--with particular reference to HLA matching and tolerance induction. Transplant Proc. 1993;25(1 Pt 1):8–12. PMID: 8438487
2. Londono MC, Londoño MC, Rimola A, O'Grady J, Sanchez-Fueyo A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol. 2013;59(4):872–879. PMID: 23578883 https://doi.org/10.1016/j. jhep.2013.04.003
3. Feng S. Spontaneous and induced tolerance for liver transplant recipients. Curr Opin Organ Transplant. 2016;21(1):53–8. PMID: 26709575 https://doi.org/10.1097/ mot.0000000000000268
4. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant. 2006;6(8):1774–1780. PMID: 16889539 https://doi.org/10.1111/j.16006143.2006.01396.x
5. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997;63(2):243–249. PMID: 9020325 https://doi.org/10.1097/00007890199701270-00012
6. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, et al., Wea ning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001;72(3):449– 454. PMID: 11502975 https://doi. org/10.1097/00007890-200108150-00016
7. Sawitzki B, Pascher A, Babel N, Reinke P, Volk HD. Can we use biomarkers and functional assays to implement personalized therapies in transplantation? Transplantation. 2009;87(11):1595– 1601. PMID: 19502949 https://doi. org/10.1097/tp.0b013e3181a6b2cf
8. Heidt S, Wood KJ. Biomarkers of Operational Tolerance in Solid Organ Transplantation. Expert Opin Med Diagn. 2012;6(4):281–293. PMID: 22988481 https://doi.org/10.1517/17530059.2012. 680019
9. Benitez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013;58(5):1824–1835. PMID: 23532679 https://doi.org/10.1002/ hep.26426
10. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012;307(3):283–293. PMID: 22253395 https://doi.org/10.1001/jama.2011.2014
11. Shaked A, DesMarais MR, Kopetskie H, Feng S, Punch JD, Levitsky J, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am J Transplant. 2019;19(5):1397–1409. PMID: 30506630 https://doi.org/10.1111/ ajt.15205
12. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant. 2004;4(12):2118– 2125. PMID: 15575917 https://doi. org/10.1111/j.1600-6143.2004.00611.x
13. Zhao X, Li Y, Ohe H, NafadyHego H, Uemoto S, Bishop GA, et al. Intragraft Vdelta1 gammadelta T cells with a unique T-cell receptor are closely associated with pediatric semiallogeneic liver transplant tolerance. Transplantation. 2013;95(1):192–202. PMID: 23222896 https://doi.org/10.1097/tp.0b013e3182782f9f
14. Li Y, Zhao X, Cheng D, Haga H, Tsuruyama T, Wood K, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation. 2008;86(12):1837– 1843. PMID: 19104431 https://doi. org/10.1097/tp.0b013e31818febc4
15. Taubert R, Danger R, Londoño MC, Christakoudi S, Martinez-Picola M, Rimola A, et al. Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated. Am J Transplant. 2016;16(4):1285–1293. PMID: 26603835 https://doi.org/10.1111/ ajt.13617
16. Pons JA, Revilla-Nuin B, Baroja-Mazo A, Ramírez P, Martínez-Alarcón L, Sánchez-Bueno F, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression with drawal. Transplantation. 2008;86(10):1370– 1378. PMID: 19034005 https://doi. org/10.1097/tp.0b013e318188d3e6
17. Stegmann KA, Björkström NK, Veber H, Ciesek S, Riese P, Wiegand J, et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology. 2010;138(5):1885–1897. PMID: 20334827 https://doi.org/10.1053/j.gastro.2010.01.051
18. Jinushi M, Takehara T, Tatsumi T, Yamaguchi S, Sakamori R, Hiramatsu N, et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology. 2007;120(1):73– 82. PMID: 17052247 https://doi. org/10.1111/j.1365-2567.2006.02479.x
19. Хубутия М.Ш., Гуляев В.А., Хватов В.Б., Леменёв В.Л., Кабанова С.А., Новрузбеков М.С. и др. Иммунологическая толерантность при трансплантации органов. Трансплантология. 2017;9(3):211–225.
20. Ciuffreda D, Codarri L, Buhler L, Vallotton L, Giostra E, Mentha G, et al. Hepa titis C virus infection after liver transplantation is associated with lower levels of activated CD4(+)CD25(+) CD45RO(+)IL-7ralpha(high) T cells. Liver Transpl. 2010;16(1):49–55. PMID: 19866484 https://doi.org/10.1002/lt.21959
21. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am J Transplant. 2009;9(9):2102–2112. PMID: 19624566 https://doi.org/10.1111/j.16006143.2009.02743.x
22. Xie XJ, Ye YF, Zhou L, Xie HY, Jiang GP, Feng XW, et al. Th17 promotes acute rejection following liver transplantation in rats. J Zhejiang Univ Sci B. 2010;11(11):819–827. PMID: 21043049 https://doi.org/10.1631/jzus.b1000030
23. Fan H, Li LX, Han DD, Kou JT, Li P, He Q, et al. Increase of peripheral Th17 lymphocytes during acute cellular rejection in liver transplant recipients. Hepatobiliary Pancreat Dis Int. 2012;11(6):606– 611. PMID: 23232631 https://doi.org/10.1016/s1499-3872(12)60231-8
24. Germani G, Rodriguez-Castro K, Russo FP, Senzolo M, Zanetto A, Ferrarese A, et al. Markers of acute rejection and graft acceptance in liver transplantation. World J Gastroenterol. 2015;21(4):1061–1068. PMID: 25632178 https://doi.org/10.3748/wjg.v21.i4.1061
25. Jhun J, Lee SH, Lee SK, Kim HY, Jung ES, Kim DG, et al. Serial monitoring of immune markers being represented regulatory T cell/T helper 17 cell ratio: indicating tolerance for tapering immunosuppression after liver transplantation. Front Immunol. 2018;9:352. PMID: 29545795 https://doi.org/10.3389/ fimmu.2018.00352
26. Mazariegos GV, Zahorchak AF, Reyes J, Chapman H, Zeevi A, Thomson AW, et al. Dendritic cell subset ratio in tolerant, weaning and nontolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant. 2005;5(2): 314–322. PMID: 15643991 https://doi.org/10.1111/j.16006143.2004.00672.x
27. Battaglia M, Battaglia M, Stabilini A, Migliavacca B, HorejsHoeck J, Kaupper T, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12): 8338–8347. PMID: 17142730 https://doi. org/10.4049/jimmunol.177.12.8338
28. Levitsky J, Mathew JM, Abecassis M, Tambur A, Leventhal J, Chandrasekaran D, et al. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology. 2013;57(1):239–248. PMID: 22234876 https://doi.org/10.1002/hep.25579
29. Levitsky J, Miller J, Wang E, Rosen A, Flaa C, Abecassis M, et al. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum immunol. 2009;70(3):146– 150. PMID: 19141306 https://doi. org/10.1016/j.humimm.2008.12.008
30. Ghazal K, Stenard F, Dahlqvist G, Barjon C, Aoudjehane L, Scatton O, et al. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity. Clin Res Hepatol Gastroenterol. 2018;42(3):237–244. PMID: 29175009 https://doi.org/10.1016/j. clinre.2017.10.001
31. Cuadrado A, San Segundo D, LópezHoyos M, Crespo J, Fábrega E, et al. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol. 2015;21(39):11016–11026. PMID: 26494958 https://doi.org/10.3748/wjg. v21.i39.11016
32. Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients. Hepatology. 2019;69(3):1273–1286. PMID: 30229989 https://doi.org/10.1002/hep.30281
33. Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant. 2007;7(2):309–319. PMID: 17241111 https://doi.org/10.1111/j.16006143.2006.01621.x
34. Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest. 2008;118(8):2845– 2857. PMID: 18654667 https://doi. org/10.1172/jci35342
35. Bohne F, Martínez-Llordella M, Lozano JJ, Miquel R, Benítez C, Londoño MC, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest. 2012;122(1):368–382. PMID: 22156196 https://doi.org/10.1172/ jci59411
36. Li L, Wozniak LJ, Rodder S, Heish S, Talisetti A, Wang Q, et al. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. Am J Transplant. 2012;12(5):1218–1228. PMID: 22300520 https://doi.org/10.1111/j.16006143.2011.03928.x
Рецензия
Для цитирования:
Сюткин В.Е., Боровкова Н.В., Новрузбеков М.С. Биомаркеры толерантности и иммунологический мониторинг при трансплантации печени. Трансплантология. 2020;12(2):126-134. https://doi.org/10.23873/2074-0506-2020-12-2-126-134
For citation:
Syutkin V.E., Borovkova N.V., Novruzbekov M.S. Biomarkers of tolerance and immunological monitoring in liver transplantation. Transplantologiya. The Russian Journal of Transplantation. 2020;12(2):126-134. https://doi.org/10.23873/2074-0506-2020-12-2-126-134
Просмотров:
950
Послать статью по эл. почте 